Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

We recently published a list of 10 Best Growth Stocks to Invest in for the Next 10 Years. In this article, we are going to ...

Crispr Therapeutics (CRSP), and Sarepta Therapeutics (SRPT) shares are lower in relation to a gene therapy death ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of Beam Therapeutics in a research report issued on Wednesday, March 12th. Cantor Fitzgerald analyst ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...

Citi raised the firm’s price target on Beam Therapeutics (BEAM) to $64 from $56 and keeps a Buy rating on the shares. With positive BEAM-302 ...